- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
Image: From remarks last week at a conference in Washington D.C., SEC Director of Enforcement Andrew Ceresney highlighted three types of Foreign Corrupt Practices Act misconduct that most often arise in the pharmaceutical industry: pay-to-prescribe, formulary drugs, and charitable contributions. More of Ceresney’s observations are inside.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
Image: SEC Enforcement Director Andrew Ceresney recently dropped new hints on FCPA risks for pharma and medical devices, plus suggestions on how to avoid those risks. “Our FCPA focus obviously covers many industries,” he said. “But the pharma industry is one on which we have been particularly focused in recent ...
Securities and Exchange Commission Chair Gary Gensler will step down from his position as the top U.S. regulator of Wall Street when Donald Trump is sworn in as president on Jan. 20, ending weeks of speculation about his future.
A publicly traded cryptocurrency mining company will pay $10 million and completely change its business model to one with “lower corruption risk” as part of a settlement over violations of the Foreign Corrupt Practices Act (FCPA), two regulators announced.
